Abstract: Modified HV1-type hirudinin which valine at the N-terminal end of the HV1-type hirudin and aspartic acid at the 5th residue of the N-terminal end were replaced with alanine and glutamic acid, respectively. A secretion plasmid into which a DNA sequence coding for a precursor with an addition of a secretion signal of neutral protease of Bacillus amyloliquefaciens at the N-terminal end of this modified HV1-type hirudin is integrated is introduced into bacteria of the genus Bacillus and the precursor is expressed intracellularly. The modified HV1-type hirudin can be efficiently secreted extracellularly while maintaining its high thrombin inhibiting activity.

Abstract: Purified BMP-2 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.

Abstract: Gene therapy utilizing an MDR1 linked fusion coding sequence has been disclosed. ADA activity has been introduced into cells using MDR1 linked fusion gene.

Abstract: A method for obtaining heterologous peptides from fusion proteins wherein at least one of the fusion components is connective tissue-activating peptide-III is provided. Hirudin, a laminin B.sub.1 peptide and platelet factor 4 are polypeptides expressed using this method. DNA sequences encoding the fusion protein, vectors containing these sequences and transformed prokaryotic hosts useful in practicing the method of the present invention are also provided.

Abstract: The present invention relates to a basic protein called phospholipase A2 (PLA2), isolated from the venom of a snake of the family Elapidae, especially of a Naja snake and more particularly Naja nigricollis and/or Naja mossambica pallida, to the fragments and derivatives of the said protein, to their methods of preparation, to pharmaceutical compositions which can be used to human and/or veterinary medicine, and to diagnostic agents in which the said protein and/or its derivatives and/or its fragments are present.The said protein comprises 118 amino acids, its molecular weight is of the order of 13,300 Daltons and its isoelectric point is of the order of 8.6.The derivatives of the said protein are modified at one of the histidines by fixation of an alkyl group of the formula R--CH.sub.2 --X.Application to the detection of tumoral cells.

Abstract: Human pancreatic elastase I can be obtained by genetic engineering.

Abstract: A process for expressing proteins in Gram(-) bacteria and providing for extracellular secretion thereof, comprising the steps: a) introducing into a Gram(-) bacterium a recombinant DNA construction comprising a promoter, a signal sequence enabling translocation and processing, and a structural gene encoding the desired protein to be expressed; b) cultivating the bacterium under conditions resulting in filamentous growth; and c) recovering the extracellularly secreted protein; a recombinant DNA construction comprising:a promoter, a signal sequence and a structural gene including a cleavage region,wherein the structural gene is of the formula:(E).sub.n (B).sub.m -Y,where n is an integer .gtoreq.

Abstract: Purified BMP-7 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and/or cartlage defects and in wound healing and related tissue repair.

Abstract: A ciliary neurotrophic factor (CNTF), particularly sciatic nerve CNTF (SN-CNTF) is claimed. The SN-CNTF described herein is a single protein species and has a specific activity that increased to greater than 25,000-fold from crude extract.Amino acid data for this SN-CNTF is also provided. In addition, methods for using this data for providing SN-CNTF probes and for screening cDNA and genomic libraries are also provided. Recombinant-DNA methods for the production of SN-CNTF are described.Nucleic acid sequences encoding rabbit and human CNTF are provided. A recombinant expression system is provided for producing biologically active CNTF.

Abstract: A CSF-1 gene promoter region is disclosed. This nucleotide base sequence is useful as a promoter for gene expression in animal cells.

Abstract: The present invention relates to new hybrid plasmids useful as vectors in recombinant DNA technology, in which Acremonium chrysogenum or Saccharomyces cerevisiae is used as a host, and to microorganisms bearing the hybrid plasmids.partially digesting a chromosomal DNA of Acremonium chrysogenum ATCC 11550 with restriction enzyme Sau 3A, said autonomous replication sequence having a molecular size of about 1.39 Kbp, and having the restriction maps set forth in FIGS. 4-6.

Abstract: Neutral protease genes from Vibrio proteolyticus or Bacillus can be cloned and expressed in gram-negative microorganisms, such as E. coli or Serratia. The functional neutral protease enzyme is expressed.

Abstract: A DNA which encodes polypeptide carrying two specific amino acid sequences and having nitrile hydratase activity; a method for producing nitrile hydratase by incubating a transformant made by the transformation with a recombinant DNA prepared by integrating the foregoing DNA into a vector in a medium and harvesting nitrile hydratase accumulated in the medium; and a method for producing amides by incubating the foregoing transformant and then converting nitriles into corresponding amides by the action of the obtained nitrile hydratase or by making a culture solution, isolates, treated cells or their immobilized products act upon nitriles to produce corresponding amides.

Abstract: DNA molecules comprising polynucleotide sequences substantially corresponding to all or a portion of the base sequence coding for an antigen of Plasmodium falciparum selected from the group consisting of the RESA antigen, the FIRA antigen, and other antigens of P. falciparum cross-reactive therewith. Such DNA molecules are capable of being expressed as polypeptide(s). Synthetic peptides or polypeptides displaying the antigenicity of all or a portion of the RESA or FIRA antigens of P. falciparum. Compositions for stimulating immune responses against P. falciparum antigens in a mammal, comprising at least one polypeptide displaying the antigenicity of the RESA or FIRA antigens of P. falciparum.

Abstract: Disclosed are DnA sequences which code for antigenic proteins, methods for identifying such DNA sequences, and antigens coded for by such DNA sequences.The first step of the method is to provide a multiplicity of DNA sequences. These sequences are then inserted into DNA expression vectors to form recombinant expression vectors. The expression vectors are inserted into suitable hosts to form transformants which express the DNA sequences. The transformants are then contacted with antibodies directed against Eimeria antigens to identify transformants containing DNA sequences which code for Eimeria antigens. These antigens are then produced from the DNA sequences identified as coding for the antigens. The antigens so produced are contacted with white blood cells which effect a cell-mediated immune response, which white blood cells are sensitized to an antigenic Eimeria protein, to thereby identify DNA sequences which code for antigens that induce a cell-mediated immune response to avian coccidiosis.

Abstract: Double-stranded cDNA is prepared from polyadenylated RNA extracted from activated human peripheral blood adherent mononuclear cells. The cDNA is inserted within a plasmid vector and then the recombinant plasmid employed to transform an appropriate host. Transformed hosts are identified and grouped into pools. Plasmid DNA prepared from these pools is hybridized with a labeled, synthetic oligonucleotide probe corresponding to a portion of the amino acid sequence of the interleukin 1 protein. Pools of host cells that provide a positive signal to the probe are identified, plated out and then employed in direct bacterial colony hybridization with the same probe, thereby to isolate the particular positive colony. Plasmid DNA is prepared from this colony and characterized by restriction enzyme mapping and sequencing by chain-termination method. The coding region for the IL-1 gene is inserted into a shuttle vector for amplification of the vector followed by expression of functional IL-1.

Abstract: Purified BMP-3 proteins and processes for producing them are disclosed. They may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.

Abstract: The present invention is directed to attenuated strains of enteroinvasive bacteria that express a peptide or protein related to an epitope of the malaria parasites of the genus Plasmodium. The bacterial strains of the invention which can multiply in a host without causing significant disease or disorder, and which express a Plasmodium-related peptide that induces a protective immune response against malaria, can be used in live vaccine formulations for malaria. In specific embodiments, a Plasmodium-related peptide can be expressed as a fusion protein, for example, with a bacterial enterotoxin.The invention also relates to methods for expression of malaria antigens or fragments thereof within attenuated enteroinvasive bacteria.In particular embodiments, the invention is directed to the expression by attenuated Salmonella spp. of epitopes of Plasmodium circumsporozoite proteins.

Abstract: Vaccines containing vaccinia virus synthetically modified to contain DNA sequences not naturally occurring in vaccinia virus and provoking an immunological response thereto in host animals inoculated with said vaccines.

Abstract: A hybrid DNA molecule is disclosed by this invention capable of cellular expression comprising the DNA sequence for protein G. Said DNA sequence has substantially the same IgC binding properties as naturally occurring protein G. The molecule may be comprised of DNA sequences coding for fragments of protein G. Moreover, said DNA sequence may code for both fragments of protein G and protein G. The DNA sequence can be isolated from streptococcal DNA.